随着出口订单快速增长，企业面临报关业务能力不足的挑战。针对企业诉求，湖州海关赴企开展靶向帮扶，结合企业产品特点与出口市场，加强"一对 一"报关合规辅导，同时展开"定制化"政策解读，帮助企业了解重点出口市场的贸易规则，提升产品国际竞争力。 包括汽车零配件在内的机电产品是浙江对德出口的主要商品。海关数据显示，2025年浙江对德出口机电产品721.4亿元，增长8.1%，占同期浙江对德出口 总值的55.1%。其中，电工器材、汽车零配件、灯具、车用锂电池出口分别增长12.3%、15.4%、13.1%和12.7倍。 作为劳密产品出口大省，浙江的诸多劳密产品在德国受到欢迎。2025年，浙江对德出口劳密产品376.2亿元，增长9.8%，占全国同类商品出口总值的 32.3%，居全国各省市首位。其中，出口纺织服装、塑料制品、玩具分别增长7.2%、16.5%和23.4%。 近年来，浙江与德国在机电、化工、汽车、高技术等领域加强经贸合作。自2018年浙江对德贸易规模首次突破千亿元关口以来，连续8年保持千亿元以上 高位，2025年浙江对德贸易规模创历史新高。据杭州海关统计，2025年浙江省对德国进出口1624亿元，同比增长8.3%，德 ...

春节期间，当大多数人还沉浸在阖家团圆的喜庆氛围中时，平凉工业园区（高新区）的不少企业却是一 片繁忙。机器轰鸣，工人忙碌，大家正以"开局即冲刺"的劲头，奏响新春的奋进曲。 走进华能平凉发电公司，生产车间灯火通明，发电机组平稳运转，大屏幕上数据实时跳动。运行人员穿 着工装，定时巡检设备、盯着燃煤储备、核对环保指标，每个环节都不敢马虎。 "越是过节，越要打起精神。"企业有关负责人表示，这个春节假期，华能平凉发电用稳定可靠的电力， 守护着万家灯火，也为园区企业生产和市区经济发展提供了坚实保障。 同样的忙碌场景，也出现在甘肃量维生物公司的生产车间。发酵罐里微生物正欢快工作，精制、干燥等 生产线全速运转，工人们分工有序，严把每道工序。 华能平凉 发电公司工作人员紧盯屏幕上的数据。本文图片均由新甘肃·甘肃日报通讯员 齐荣摄 新甘肃·甘肃日报记者 田丽媛 通讯员 齐荣 企业生产不停歇，园区服务也不打烊。春节前夕，平凉工业园区党工委、管委会提前部署，组织工作人 员进企业、查矛盾、解难题，送上新春祝福。走访中，他们详细询问生产计划、用工保障、安全生产等 情况，精准对接企业遇到的难点，积极帮助解决。企业负责人纷纷感慨："园区服务这 ...

Core Viewpoint - Chongqing Weier Kangqi Hui Pharmaceutical Co., Ltd. has been found to have safety hazards, leading to a suspension of sales as a risk control measure by the Chongqing Drug Administration [2] Company Summary - Company Name: Chongqing Weier Kangqi Hui Pharmaceutical Co., Ltd. [2] - License Number: 渝AA0230793 [2] - Business Address: No. 827, Section 33, Erhuan South Road, Tangxiang Street, Dazhu District, Chongqing [2] - Warehouse Address: No. 827, Section 33, Erhuan South Road, Tangxiang Street, Dazhu District, Chongqing, covering multiple floors [2] - Business Scope: Includes chemical raw materials and their preparations, antibiotic raw materials and their preparations, biochemical products, traditional Chinese medicine, Chinese medicinal materials, Chinese medicinal pieces, biological products, protein anabolic agents, and peptide hormones [2] Regulatory Actions - The Chongqing Drug Administration has implemented a sales suspension for the company due to identified safety hazards [2] - The company is required to strictly fulfill its primary responsibility to eliminate quality safety hazards and submit a rectification report to the Chongqing Drug Administration [2] - The risk control measures will be lifted only after a re-inspection confirms compliance with the necessary conditions [2]

针对上述提问，瑞普生物回应称："投资者您好！生物制品13%税率一般计税政策不影响2025年经营成 果；2026年实施后短期实际税负将有所上升。公司产品线齐全，产业链完善，通过优化产品定价与结 构，优化供应商与采购管理，降低税率调整带来的影响。公司严格依规纳税，扎实做好经营管理，为公 司及股东创造价值。相关情况请以公司定期报告披露为准。感谢您的理解与支持！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向瑞普生物提问："生物制品2026年1月1日由3%税额改为13%，对公司盈利水平影 响有多大？" 来源：市场资讯 ...

Core Viewpoint - The article discusses the cancellation of the simplified VAT policy for biological products, including vaccines, effective from 2026, which will require companies to adopt a general taxation method instead of the previous 3% simplified rate [3][4]. Summary by Sections VAT Policy Changes - The Ministry of Finance and the State Administration of Taxation announced that the simplified VAT policy for biological products will no longer be applicable starting this year, as outlined in the recent announcement [3][4]. - Previously, companies could choose to calculate VAT based on a 3% rate on sales of biological products, but this option will be removed [5]. Impact on Companies - Experts indicate that leading companies with well-established supply chains may not see an increase in tax burden, while smaller companies with insufficient input tax credits may face higher taxes [7]. - Companies are advised to reassess their supplier and customer relationships and adjust pricing strategies in response to the new tax policy [7][8]. Recommendations for Businesses - It is recommended that companies in the biological products sector conduct an immediate assessment of the tax burden impact, optimize supplier selection, and ensure compliance with VAT invoicing [7]. - Companies should also consider the tax burden changes in product pricing and contract negotiations with downstream clients [7]. Exceptions to the Policy - Certain biological products, such as anticancer drugs and rare disease medications, will still retain the simplified 3% VAT policy until the end of 2027 [8][9].

Core Viewpoint - The stock of Zhifei Biological experienced a decline in price and significant net outflow of funds, indicating potential challenges in its financial performance and investor sentiment [1][2]. Group 1: Stock Performance - On February 4, Zhifei Biological's stock rose by 2.03%, reaching 17.57 CNY per share, with a trading volume of 235 million CNY and a turnover rate of 0.96%, resulting in a total market capitalization of 42.059 billion CNY [1]. - Year-to-date, the stock price has decreased by 6.89%, with a decline of 1.62% over the last five trading days, 9.11% over the last twenty days, and 18.36% over the last sixty days [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 7.627 billion CNY, a year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -1.206 billion CNY, reflecting a year-on-year decrease of 156.10% [2]. - Since its A-share listing, the company has distributed a total of 7.318 billion CNY in dividends, with 3.194 billion CNY distributed over the past three years [2]. Group 3: Shareholder Information - As of January 20, 2025, the number of shareholders for Zhifei Biological was 121,000, a decrease of 1.56% from the previous period, while the average number of circulating shares per person increased by 1.58% to 11,686 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 33.5608 million shares, and several ETFs, all of which have seen a reduction in their holdings compared to the previous period [2].

2025年半年报显示，期内公司实现营业收入96.99亿元，实现净利润1.63亿元。 其中，在药品销售方面，嘉事堂是北京市医药商业龙头企业，北京基药主要配送商之一，服务北京二三 级医院300多家，覆盖率达99%。 在医疗器械方面，嘉事堂拥有心脑血管等高值耗材细分市场占优的渠道和终端网络，形成全国布局，重 点区域为长三角、粤港澳大湾区、京津冀、西南、西北区域，与2100多家医院建立终端销售渠道。 2月4日早间开盘，嘉事堂股价复牌。截至发稿时间，每股报价17.02元，涨幅3.78%，总市值49.62亿 元。 消息面上，2月3日晚间，嘉事堂发布公告称，公司股东光大实业、光大健康与同仁堂集团签署了《股份 转让协议》，协议约定光大实业、光大健康分别将其持有的公司约4118万股股份、4187.6万股股份转让 给同仁堂集团。转让价格为人民币17.59元/股，转让价款总计为人民币14.6亿元。 本次交易完成后，公司控股股东将变更为同仁堂集团，实际控制人将变更为北京市人民政府国有资产监 督管理委员会。 公告表示，本次协议转让尚需经主管国有资产监督管理部门批准、通过国家市场监督管理总局经营者集 中反垄断审查、通过深圳证券交易所合规 ...

2月3日晚间，嘉事堂发布公告称，2月2日，公司股东光大实业、光大健康与同仁堂集团签署《股份转让 协议》，协议约定光大实业、光大健康分别将其持有的公司4118.08万股股份、4187.64万股股份转让给 同仁堂集团，转让价款总计为14.61亿元。 此次交易完成后，公司控股股东将变更为同仁堂集团，实际控制人将变更为北京市人民政府国有资产监 督管理委员会。公司股票自2月4日开市起复牌。 图片来源：公司公告 截至1月27日收盘，嘉事堂股价报16.4元/股，市值为47.8亿元。 尚需多项审批 公告显示，此次股份转让的每股价格为17.59元，转让总价款为14.61亿元。其中，光大健康转让股权占 公司总股本的14.36%；光大实业转让股权占公司总股本的14.12%。交易完成后，二者将不再持有公司 股份，同仁堂集团则以28.48%的持股比例成为控股股东。 公开资料显示，嘉事堂于1997年成立，2010年在深交所上市，2018年进入光大体系，是光大大健康业务 板块主要平台。嘉事堂主要业务涵盖二三级医院销售、社区医疗中心销售、物流配送、连锁零售，经营 范围包括药品、生物制品、医疗器械、中药饮片等。 业绩方面，公司2025年前三季 ...

Core Viewpoint - The stock of Zhifei Biological has shown fluctuations, with a recent increase of 2.07% on January 29, 2023, despite a year-to-date decline of 3.39% [1] Group 1: Stock Performance - As of January 29, 2023, Zhifei Biological's stock price was 18.23 yuan per share, with a trading volume of 5.20 billion yuan and a turnover rate of 2.08%, resulting in a total market capitalization of 436.39 billion yuan [1] - The stock has experienced a 7.05% increase over the last five trading days, but a decline of 3.95% over the last 20 days and 14.37% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Zhifei Biological reported an operating income of 76.27 billion yuan, a year-on-year decrease of 66.53%, and a net profit attributable to shareholders of -12.06 billion yuan, reflecting a year-on-year decrease of 156.10% [2] Group 3: Shareholder Information - As of January 20, 2023, the number of shareholders for Zhifei Biological was 121,000, a decrease of 1.56% from the previous period, with an average of 11,686 circulating shares per person, an increase of 1.58% [2] - The company has distributed a total of 73.18 billion yuan in dividends since its A-share listing, with 31.94 billion yuan distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, major shareholders include Hong Kong Central Clearing Limited, holding 33.56 million shares, and several ETFs, all of which have seen a decrease in holdings compared to the previous period [3]

Group 1 - The core viewpoint of the news is that Dajia Weikang's stock performance and financial metrics indicate a mixed outlook, with significant fluctuations in financing activities and a notable decline in net profit despite revenue growth [1][2]. Group 2 - On January 22, Dajia Weikang's stock rose by 3.11%, with a trading volume of 219 million yuan. The financing buy-in amount was 19.63 million yuan, while the financing repayment was 24.06 million yuan, resulting in a net financing buy of -4.43 million yuan. The total financing and securities balance reached 88.92 million yuan [1]. - As of January 22, the financing balance of Dajia Weikang was 88.58 million yuan, accounting for 3.10% of the circulating market value, which is above the 90th percentile level over the past year [1]. - On the same day, Dajia Weikang had a securities lending repayment of 100 shares and a securities lending sell of 700 shares, with a selling amount of 9,744 yuan. The remaining securities lending volume was 24,300 shares, with a balance of 338,300 yuan, also above the 90th percentile level over the past year [1]. - As of December 31, Dajia Weikang had 16,100 shareholders, an increase of 0.68% from the previous period, while the average circulating shares per person decreased by 0.68% to 8,562 shares [2]. - For the period from January to September 2025, Dajia Weikang achieved operating revenue of 4.13 billion yuan, a year-on-year increase of 3.69%, but the net profit attributable to the parent company was 5.10 million yuan, a significant decrease of 86.02% year-on-year [2]. - Dajia Weikang has distributed a total of 42.59 million yuan in dividends since its A-share listing, with 35.57 million yuan distributed over the past three years [3]. - As of September 30, 2025, Dajia Weikang's top ten circulating shareholders saw the exit of the Noan Multi-Strategy Mixed A fund from the list [3].